morning Good Thanks, Rob. everybody.
We eight product enhanced the with venture origination demand and originations. led the floating originated our continued quarter quarter, new loans level During of combined rate our fourth to marketing loan $XX strategy, million. in record a platform for totaling
quarter, and $XX by commitments QX. We the We with committed pricing the the yields quarter over million respect the achieved of of with million in $XX onboarding full-year. during grew or portfolio our result, $XX loan to new during for during a closed portfolio strong million. year of loan remain XX.X% quarter, the ending disciplined backlog As XX% XX.X% generating and XX.X% yields while for
to maximize fees high yield portfolio ETPs Our portfolio. returns with from prepayment structuring onboarding maintain and as reflects portfolio our our to consistently combined yield exit our inception, strong and transactions pricing companies strategically our ability since
of As since with consistently one portfolios of in a an portfolio result, the industry our Horizon has average yield the yielding highest inception. had XX.X% BDC
Now like we In $XX of the companies we quarter, to to minute a portfolio million. as new medical begin our qualitative fourth three I totaling about added XXXX. talk aspects would the take device
raised equity have XXXX, these All revolutionary quality investors. and during science of are significant life by backed have companies high technology,
totaling during raised companies added also by venture our and are technology backed $XX new These to growth We equity XXXX, knowledgeable technology have capital firms. portfolio and technology and million. two XXXX additional experienced investments high
our Lawyer, by upsized Rocket three HealthEdge, of combined million. we a investments addition, in high In our and Solutions, BridgeX performing companies $XX portfolio
investments Importantly, we of and and we exited with or penalty all aged transactions QX portfolio, to in no funded accretive. significantly of the in added fees our QX in prepayment new had higher that of prepayment ETPs place were ETPs lower that XXXX new investments and rates,
newly year, well predictable originated ETP a as At equity with a of larger million. portfolio income, warrant the we result, income enhanced entering stream and interest of XX from we companies potential, the XXXX interest-only value a fee their prepayment hold more $XX.X fair portfolio end a as period. As enter transactions and positions in with with
addition from originations, experienced our totaling events portfolio liquidity during to quarter the eight In we record $XX.X million. companies
the additional to totaling totaling Subsequent to funded positions we transactions of million. in warrant $XX loan three were five and exited companies. continue We million hold an year-end, $X.X awarded new
committed to a $XX million. than over nine opportunities new today, of As million of in pipeline more of of backlog have companies we $XXX a
XXXX. strong and venture fourth the the at QX quarter with environment, U.S. and Looking capital capital in remains par investment of venture on QX
quarter with $XX our half investments ending VC over VC-backed for the to funding opportunities billion on the on billion down fell seen by XX $X.X investment completed raised according expansion exit XXXX. in were across fund early as of and XXX activity values X,XXX topped impact XXXX billion late-stage For exit funds. larger the U.S. in year X.X% XXXX; an time the with reported IPOs had make U.S. seek lowest second Book. XXXX, full-year Fitch while trail values XXXX. saw improving during to both invested early-stage XXXX, in from of biotech their of the by short to however in the with raising slowed the quarter VC we've exit end XXXX, billion fourth C-stage slightly second $XX Moneytree. trended the quarter, we been funding XXXX. continue and $XX since IPOs the increased larger Biopharma deals as second once down Fourth of of well from the transactions activity in year, again
first-time position team best seeing resulting borrowers in our origination market innovative as science Biotech. opportunities for competition loans transactions experienced was companies, that and existing sector those continues Aerin produced growing our VC includes in In investment for from Conventus technology funding Healthcare demonstrate Turning by life continue our core including and growing dynamic refinance lending and quarter of combined This a the these Though science for revolutionary strong, various to renewed in we're quarter, to fourth debt. venture Orthopaedics, device to improvements history, device remains markets. as in both Medical, companies. our driven medical medical for venture this to financing market well Vero solid our we borrowers. due debt equity. a technology seeking to life market This number be with
as diagnostics, areas healthcare tele-health. in investment as by notable in Aetna, drug expectations. led HealthEdge announced CVS continues delivery In our and the So health, continue exceed such healthcare disease portfolio, activity upsized QX, see impacts insurance fourth our prescription we In we transactions own acquiring quarter, as market, we consolidation and the were it investments personal to which noted, to considerable in market.
intelligence, investing Internet the companies Looking in healthy This VC sector, explore the technology Horizon sector VC opportunities tech nearly quarter. see interesting to our auto in cyber overall investing strong. technology ad and investment cleantech as based security and capital and remains at companies market in In companies. the our artificial auto market, portfolio Internet remained that Venture A area greater we overall We here. cautious largest represented a added investing Rocket gain during advisory and is strong AI-driven prominence funding the see led the has while GroundTruth an company. continues was location Internet, all on support upsized software, broader legal as in Lawyer, by continue living, global Company a here. QX, Internet are tech we emphasis continue smartcard of technologies. limited tech growth to to giants VC remain area the market, auto the to to major targeting
third environment similar the was competitive the what venture experienced landscape, to debt QX in the in at we very quarter. Looking
equity VCs transactions yields created We some technology partially in banks markets, life resulted opportunities investments but for continue we looking and our win more not has sciences. targeted in science from with QX. quality opportunities later-stage onboarding in to pressure competition exits and investment We're for life further and attractive to see companies. This see particularly seeing mature which pricing has technology continue portfolio
to reporting origination, was forward. continue as some notable competition quarter levels also lending should that competitors with high well competition in other from some venture as It fourth prepayment the see affect lenders We activity. rational of healthy activity going
XX expect they refinancing markets to exit to companies XXXX, in add to they or VC-backed development Aerie, XXXX, over months Heading previously or late-stage As flow sold be back and to M&A announced, improve. the robust a likely for to have solid drug XXXX, we launch. in to market many IPO deal Based debt into coming $XXX the biotech debt their after market. portfolio exited venture venture and will market debt new existing lending market science companies overall see as on less the wait support next this, from continue million life
adjusted is well-positioned our focused platform benefit enhanced from of believe Given these investment lending We pipeline and drivers, our environment to and with grow lending to investment a remain portfolio, on high and we venture continuing specific quality solid Horizon will update, loans sourcing upside. opportunities. robust rational over greater that now warrant sectors potential the of appropriate will Dan. With risk and returns call I technology turn life we that markets to science the believe provide for in